A new hope for Australians with progressive multiple sclerosis

In a pioneering move, Australia is set to embark on its first-ever adaptive clinical trial targeting progressive multiple sclerosis (MS) starting January 2024. 

Backed by a substantial $4 million initial funding, the PLATYPUS trial aims to reverse neurological damage in individuals suffering from this debilitating form of MS. Unlike traditional trials, PLATYPUS will concurrently test two repurposed drugs, metformin and alpha-lipoic acid, potentially providing faster and more promising results. The trial is an acronym for ‘Platform adaptive trial for remyelination and neuroprotection in multiple sclerosis.’

Addressing the unmet need

With an estimated 13,000 Australians affected by progressive MS, there is a critical lack of treatment options for this relentless form of the disease. PLATYPUS emerges as a major milestone and offers hope to fill this treatment gap, marking the first adaptive clinical trial for MS in Australia.

Funding and collaboration:

MSWA, formerly known as the Multiple Sclerosis Society of Western Australia, is leading the funding with $3 million and expresses pride in supporting this ambitious project. The trial, an extension of the successful OCTOPUS trial launched in the United Kingdom in 2023, involves collaboration with 20 academic and healthcare institutions across Australia. This collective effort aims to recruit over 250 participants, accelerating the pace of discovery.

Repurposed drugs and potential breakthrough:

Led by Neurology Professor Simon Broadley, PLATYPUS will test the efficacy of metformin and alpha-lipoic acid, drugs with promising indications for neuroprotection and myelin repair in MS. The adaptive design of the trial allows for quicker results, addressing the urgent needs of individuals with progressive MS.

Community impact:

Community voices, including MS Australia Chief Executive Officer Rohan Greenland and diagnosed individual Nigel Caswell, express excitement and hope for the potential breakthroughs that PLATYPUS may bring. With a combined $4 million grant from MSWA and MS Australia, the adaptive trial promises a transformative impact on the lives of those living with progressive MS.

The PLATYPUS trial signifies a significant leap in Australia’s pursuit of effective treatments for progressive MS. The adaptive design, substantial funding, and collaborative approach position the trial as a beacon of hope for the MS community. As the trial unfolds in 2024, there is anticipation for groundbreaking outcomes that could reshape the landscape of progressive MS treatment in Australia and beyond.

What do you think of this news? Share your thoughts in the comments below.

Subscribe to our FREE weekly e-newsletter for exclusive updates, news, and in-depth information.